On August 21, 2023, Qingdao Baheal Pharmaceutical Co., Ltd. (referred to as "Baheal Pharmaceutical", 301015.SZ) and Gilead (Shanghai) Pharmaceutical Technology Co., Ltd. (referred to as "Gilead Sciences") signed a strategic cooperation agreement. Representatives from both companies, including Jin Fangqian, Global Vice President and General Manager of Gilead Sciences China, and Fu Gang, Chairman of Baheal Pharmaceutical, attended the signing ceremony.

In this collaboration, the two parties will leverage their respective strengths: Baheal Pharmaceutical's expertise in commercialization and its marketing network covering national retail endpoints, combined with Gilead Sciences' frontier knowledge and extensive experience in virology and other disease areas. Together, they will explore innovative medical solutions and service models. This cooperation aims to bring tangible benefits to patients by improving the accessibility of innovative drugs, increasing disease awareness, ensuring medication safety, and strengthening integrated disease management. Jointly, they are committed to contributing to the realization of the grand goal of "Healthy China 2030" at the earliest possible date.

  At the Signing Ceremony

Since its establishment in California, USA in 1987, Gilead Sciences has consistently committed to "breaking the impossible," bringing innovative therapies to seriously ill patients through bold and transformative scientific innovation. In 2017, Gilead officially began its commercial operations in China. Within a few short years, its Chinese operations have covered three major disease areas: virology, mycology, and oncology. To date, Gilead has received domestic approval to market a total of 11 innovative drugs targeting chronic hepatitis B, hepatitis C, HIV prevention and treatment, invasive fungal diseases, and triple-negative breast cancer. Among these, eight drugs have been included in the national medical insurance directory.

Baheal Pharmaceutical, a leading health brand commercialization platform listed on the A-share market, focuses its core business on the brand operation of globally superior healthcare products. By creating a "Brand Highway", it provides comprehensive commercialization solutions for upstream industrial enterprises, enhances operational efficiency, and promotes the standardized development of the industry. Currently, the operating product matrix covers four major categories: over-the-counter (OTC) and general brand commercialization platform, prescription drugs such as OTX, severe disease medications including oncology, and high-end medical devices.

During the signing ceremony, Jin Fangqian stated: "With a people-oriented and patient-centered approach, Gilead China, while introducing globally innovative therapies and covering a wider range of disease areas, has been actively exploring innovative collaborations with domestic parties. We look forward to joining hands with like-minded partners like Baheal to further enhance the accessibility and affordability of innovative drugs, benefiting more patients in need."

Regarding this collaboration, Fu Gang stated, "Baheal Pharmaceuticals is committed to optimizing medical scenarios through technological innovation, promoting the introduction of products with real clinical application value into the market, and improving treatment plans. In partnering with Gilead, we hope that our combined efforts will bring more treatment options and clinical benefits to seriously ill patients in China, better satisfying the diversified health needs of patients."